Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
P/B ratio for Petros Pharmaceuticals, Inc. (PTPI)
P/B ratio as of 2023: 0.25
According to Petros Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.25. At the end of 2022 the company had a P/B ratio of 0.29.
P/B ratio history for Petros Pharmaceuticals, Inc. from 2018 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.25 |
| 2022 | 0.29 |
| 2021 | 1.02 |
| 2020 | 2.45 |
| 2019 | 0.85 |
| 2018 | -2.37 |